Skip to content
Back to the Guavy Wire
Stocks

Isomorphic Labs raises $5 billion for AI drug discovery

Instruments
GOOGL
Share

Isomorphic Labs, the AI-driven drug discovery startup founded by former Google DeepMind CEO Demis Hassabis, has secured a massive $5 billion in its Series C funding round. The announcement came just three-and-a-half months after Hassabis stepped down from his role at DeepMind, which Google acquired in 2014. The round was co-led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz and Alphabet, Google's parent company. The funds will be used to advance the design and development of new medicines using artificial intelligence.

Hassabis, who has been at the helm of Isomorphic Labs since its spin-off from DeepMind in 2021, expressed his vision for the company. 'When we founded Isomorphic, our conviction was that biology could be understood and modelled at the most fundamental molecular level and radically accelerated through AI,' he stated. The latest investment will enable the company to build foundational biology models, deepen disease understanding, and move its therapeutic programs toward clinical trials.

Isomorphic Labs is developing a proprietary AI-powered drug design engine and a pipeline of therapeutic candidates. The company aims to deliver the next generation of medicines through its innovative approach. This funding round comes amid a record year for drug discovery startups, which have raised $23.2 billion in 2026, according to Dealroom. Other major players in the space, such as OpenAI and Anthropic, have also been investing in AI tools for drug discovery.

The startup last raised funds in May, with a $2.1 billion Series B round. The significant increase in this latest round underscores the growing confidence in AI's potential to revolutionize the pharmaceutical industry.

More on Stocks